ABSTRACT
Drug likeness is a qualitative conception applied in drug design for how “drug-like” an element is related to factors such as bioavailability and extensively incorporated into the initial phases of lead and drug discovery. It is projected from the molecular structure earlier that the substance is at least synthesized and tested. A traditional technique to estimate drug likeness is to verify compliance of Lipinski’s Rule of Five, which contains the amounts of hydrophilic groups, molecular weight, and hydrophobicity. Methods to recognize drug-like molecules are grounded on their capability to discriminate known drugs from nondrugs in the groups of compounds by associating with one or more of the succeeding extensively available drug databases. There are different databases to categorize drug-like molecules which are based on their capability to discriminate known drugs from nondrugs in the set of compounds and have different methods to assess the drug likeness. The concept of drug likeness has numerous applications in drug discovery.
